That headline is not in my words, of course (that’s why I use those handy little quotation marks), but it’s the headline from the latest Nick Hodge ad that’s been getting a lot of attention from Gumshoe readers.
Hodge is pitching this new device, which apparently faces a big moment on June 30, as a way to, in his words….
“Eradicate every disease from Zika, ebola, and HIV… to all kinds of cancer…
“Unleash a $57 billion wave of wealth…
“Send the one tiny $10 company with over 1,000 patents on it soaring to dizzying heights…”
Is that enough for you? Tragically, it will neither provide a virtual reality experience nor enhance your self-driving car… but otherwise, apparently we’ve got it all covered.
And apparently this new company is awaiting some big news from the FDA on June 30 — which, naturally, tends to cause investors to get sweaty hands and the shakes as they imagine the wave of wealth that’s moments from consuming them. So what’s he talking about? Is it real? Let’s dig into the clues and check it out.
(Assuming, of course, that you don’t wish to sign up right away for Hodge’s Early Advantage at $799/year — you can do that, if you want, but don’t do it just to learn about a “secret” stock… if you let us tell you about it first, you’ll have a better chance at giving the idea a prudent screening before you invest.)
How does Hodge hint at this secret company? Here’s a taste:
“I call it ‘Project Zero.’
“That’s because it promises to eliminate disease at the single source… before it forms in our own body.
“In the same lab that developed the vaccines for once-fatal illnesses like measles and pneumonia…
“A team of Philadelphia researchers has been working on a device that could eclipse them all.
“And now they’ve done it.
“They’ve created a needle-free technology — one that promises to end some of the worst diseases now ravaging mankind… all without side effects.”
The ad also includes a picture of the device, and given that and the chatter about curing Zika, Ebola, HIV and all kinds of cancer we can jump right ahead to the answer for you — this is a pitch for Inovio (INO).
The little handheld electroporation “gun” that they show in the ad is here on Inovio’s website, should you require any additional confirmation.
This is not a new promise, or a new idea being teased — Inovio has been touted several times in the past by several different newsletters, and can be counted upon to surface in the annals of teaserdom whenever there’s a scary new epidemic being talked about, whether it be Ebola or Zika or, in previous years, Bird Flu or other mutant influenzas, among other bugs. Most recently, I concluded that Dave Lashmet at Stansberry was touting Inovio as his “best idea right now” in February.
What’s the June 30 deadline all about? Well, I hesitate to say “hooey”, but ad copywriters routinely overstate the importance of near-term catalysts — they know that you’re much more likely to sign up for a newsletter if they promise big news in a month or two, than if they just say that a revolutionary technology might eventually get approved and lead to profits in a few years. My guess would be that Hodge is referring to the fact that they’ve been working with the FDA on planning for a Phase III trial to start in their lead compound this year (that’s VGX-3100)… here’s what they said in the quarterly press release:
“Inovio held constructive meetings with both FDA (end of phase II) and European Medicines Agency (EMA) providing an affirmative path forward toward an indication for VGX-3100 to treat HPV-16/18-related high grade cervical dysplasia that is consistent with our previously reported expectations to start a pivotal phase III registration study in 2016.”
They also have data on their MERS, Ebola and planned Zika trial likely to come out in the relatively near future (though not necessarily very soon), though all of those are behind VGX-3100 in the calendar and probably quite a long time from commercialization (unless there’s some pandemic that forces fast approval). I have no idea how things will work out for Inovio, but that appears to be the company Hodge is hinting at.
And I know we’ve got a great many biotech investors in Gumshoedom these days, so if those of you who’ve delved into the science have any opinions to share, well, I’m sure we’d all be delighted to hear them with a comment below. Dr. KSS, who leads biotech discussions for our Irregulars, has been very negative about Inovio for years (sample comment here).
"reveal" emails? If not,
just click here...
All I can tell you from their financials, not knowing much in detail about the company, is that after raising a bunch of money they are probably sitting on enough cash to keep going for a while — they think they’re funded through the anticipated Phase III trial for their Cervical Dysplasia therapeutic vaccine (that’s the VGX-3100 I mentioned). They’ve also been pretty good about getting other folks — often DARPA or other arms of the government — to fund their early infectious disease vaccine programs. So they probably won’t go broke anytime soon… but whether this summer will really bring exciting news for Inovio, or whether Zika will spread further this Summer and inspire more government funding or more stock touting that could drive the shares up, that I don’t know. I await your wisdom, dear readers.
I like the stuff that I’ve read from Dave Lashmet. I think that he’s a straight shooter. If he says buy INO, then I’m going to buy INO. Dr. KSS might think that he knows medical topics, but I doubt that I’m going to make any money listening to him.
One more thing. At the bottom of Inovio’s press release that came out today, it lists “partners and collaborators,” one of which is the University of Pennsylvania. Did anyone read yesterday’s “Parade Magazine” that comes with most Sunday Newspapers? The cover story was about a woman who was set free from Multiple Myeloma with immunotherapy. Where was she treated? At the University of Pennsylvania. IF, and I don’t know this, Inovio was involved in her treatment, this would be a HUGE deal. In the article, it says, “She was determined to get into the trial funded by drug manufacturer Novartis.” It was funded by Novartis, but who developed the drug?
Dr Carl June has been working on reengineering T cells for year. Google Carl June, Fighting Fire With Fire, and get it from the source.
ADXS was the company in my opinion.
9 May 2016. I hope Nick Hodge is right. I bought this stock in 2010 when it was .875 cents per share. Then a reverse split (I went from 15,000 shares to around 3800.)
I have been patient and I have made a few coins, but nothing spectacular. I don’t have a high regard for Nick. Normally, when I hear his name I run for the exit. Let’s hope he is right, big time.
it’s not about HOPE. It is about DD. Do your research about the company! Inovio is SOLID!!!!!!!!!$$$$
4 self serving management imo
What would we do without the dream team…….another $799 pa down the toilet? $49 for SG sounds like a way better price.
Thank you for the information. I really appreciate your commentaries on these stock presentations. You save us subscription purchases which can be very costly. Thanks for giving the symbols, and the Company names also.
May I make a suggestion. Could you put the company that is being touted as the next best thing since sliced bread in “BOLD”??? Thank You.
Is Nick selling his report or promoting the company’s sale of shares. I am interestedin the sokes of the company but not buying the report.
By electroporation, I assume they’re referring to the term in Physics whereby they bombard a substrate with enough charge for it to assimilate full cell saturation. This is really a misnomer. What they’re probably referring to is something akin to Bob Beck’s microbe electrifier or blood purifier. By passing an electric current through the blood, all microbes can be killed at different frequencies. This began from work done by a Dr. Kaali at Albert Einstein School of Medicine, but he and his colleagues went mum shortly thereafter in the 90’s.. Was supposed to wipe out AIDS. Makes you wonder.
You have no clue…….. google “electroporation” easy as pie!!!!!
Inovio obtained the needle free technology from Bioject. That purchase left common stock holders of Bioject with nothing (I had 10,000 shares) so it was the same as a bankruptcy but a more subtle taking of share value. Inovio is the leader in electroporation based delivery of DNA vaccines and they know what they are doing. Electroporation based DNA vaccines work but they are handicapped by having to have a device for delivery as apposed to a simple syringe. Also it hurts.
I invested in INO several years ago & was fortunate enough to double my money. I’m still holding 2k shares from my original purchase (split adjusted at 2.04/share) & won’t be selling any time soon. I feel there is still plenty of upside for this company.
If Dr. KSS hates it, that’s a good sign.
Umm…..uhh……do I detect a barely audible note of snark having to do with (dare I even suggest it) a perceived slight disconnect between KSS-love of a stock and its performance, price-wise?
My money is on Medizone
I’m not sure what is the bigger joke,.. this “article” or Dr. Kss… LOL! This Doc,.. like many of his ilk wouldn’t recognize the evolving field of immunology and oncology… I read enough of your post to quickly recognize neither you nor “Dr.” Kss understand the next generation of biotech… SCAM city….
This is great. An anti-Kss thread. Keep it over here and have a blast !
Tread slowly like money morning and several others their a more or less pump and dumper follow the volume at the close out date.
I’ve been in INO since early 2012 and trading in and out a few times , (with only half my position), has left me far enough ahead that I’d remain considerably in the green even if they went to zero today. I’m all done with that now though. Haven’t sold a single share into this most recent run-up. From here on I’m holding onto my full position come Hell or high water.
LOL,, I figured some Dr KSS bashing would come out here! And so it did!
well, I’m not gonna enter into any of that. While I don’t see the good Dr. KSS as the Holy, All- Knowing on all things biotech as lot’s of you do, I do recognize his education and training and experience and contacts in the field should definitely not be ignored. But having said that, I have much more faith in Dr Kim and INO. And the fact that Dr KSS (hates) INO does not intimidate me in the least.
I’m a little skeptical that this will generate significant income in the short to medium term. For me there are too many questions still and too few upsides. Generating an immune response against an antigen of choice by transfecting the host muscle tissue with that antigen seems like a good way to kill the muscle that was transfected. Also, with gardasil/HPV vaccination effectively preventing HPV associated cancers, I don’t see that targeting this with an immunotherapy is much of a business plan. Potential upside if they can get good results against some of the trickier viruses out there but the flu vaccine is pretty cheap and widespread and they haven’t really got a lot else to excite me.
You have no idea what you are talking about!
Many years to product. Many things can happen in the course of clinicals. I like to think deep and separate the hopefuls from the losers. Bios are my most entertaining in any given day and spend a lot of time reading. I always keep in mind when science messes around with DNA, years later side effects can show up and cause an entirely different problem. So we weigh the risk/reward and the FDA carries the burden to prevent such things from happening, so we like to think.
You have mistaken Inovio with the Crispr, CAR-T companies! (editing DNA) Do your DD
All new biotechs are many years to the finish. Patience and years are the key
I don’t doubt that money can be made even by investing in Tono-Bungay. Since I’m not an MD or PhD with specialized analytical knowledge, I remain grateful to and appreciative of Dr. KSS, who so generously shares his erudition. So go ahead; let your stuff double. I try to stay with quality. I probably miss some good bets and hope you all make a fortune from electroporation, but so far following Dr. KSS is one of the best investment things that has ever happened to me.
I love the reference to Tono-Bungay. HG Wells had it right.
Judging from the comments section this article should be re-titled as a Gieco commercial.
If you’re a troll that’s what you do.
A troll’s gotta troll.
Is the Yahoo board broken or something?
Opp Right On!!! Well said.
What they have is a delivery device. The success or failure of the treatment depends on what this magic gun delivers. It may be effective in some diseases/conditions & not in others. Also, for some infections, needles work just fine. As to the likelihood that huge profits are waiting to be scooped up, I haven’t the least notion. It’s like betting on a beauty contest. It doesn’t much matter which of the contestants you think is the most gorgeous. You have to try to guess which one the judges will pick.
Thank you Doc Gumshoe! You are absolutely correct about electroporation. This is an old technology that HAS been proven in the past to delivery vaccine directly in the cell with upto 1000 times more potency. What has fail previous is the vaccine itself, toxicity levels. Imagine the good and bad multiplied by 1000 is fatal. Dna vaccines have also been around, these have failed in the past since not enough of the vaccine entered into the cell walls to make it effective enough. Now Inovio has combined their improved Synthetic Vaccines with Electroporation. The purchase of BIoject gives them the tech to make needleless Electroporation Devices. Inovio has even more methods to improve their Immunotherapy franchise. This is one exciting and innovative little gem!
Looks like Surgibot- got the boot today from TRXC so let’s call it SurgiBOOT. Fool me once, shame on you, fool me twice, shame on me. Good thing I didn’t buy back into the hype and was able to dump and get out at $2.25, the first time. I mean really, with all those industry experts and former FDA experience ya think they could pass the SE hurdle. Now focused on ALF-X with no EU sales well into the second quarter of FY-16. I saw a picture on Twitter with all those playing what looked like a glorified amusement game at Arab Health and yet no takers. The best thing the Pope can do now is close down the vatican and put the priests on the street. Conserve what cash is left. This one is apparently going down and may not ever get up again. Moving what’s left to EDAP, a real robotic hopeful. Good luck, game over for me.
Timothy !yea you troublemaker you are wrong ,you paid a measley 49 bucks just so you can piss in somebody’s cornflakes. Screw up the rest of their day ,NO, you won’t. I think you’re broke and have nothing to do . Your 49 $ should be in your gastank, your going to need it!
What is the tiny lab in North Carolina that Agora is talking about?
What is really happening with TRXC, Travis?
It looked so hopeful a while back (January).
Any hope for SurgiBot and the FDA?
ROBERT H.
I haven’t followed it, but Dr. KSS has written quite a bit about them since the FDA response, and there’s been a lot of reader discussion. No one knows for sure, of course, but I’m not in the stock personally — partly because the uncertainty is too dramatic.